ClinicalTrials.gg
RecruitingNCT07042672BETTER-GLP1Updated Sep 15, 2025

Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

An observational study in Binge Eating Disorder Associated With Obesity, Binge Eating Disorder and Eating Disorder Binge, sponsored by Haukeland University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Haukeland University Hospital · Observational

How we know · 5 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED.

The primary objective of this study is to evaluate the impact on BED symptomatology, while the secondary objectives include examining the potential adoption of alternative harmful coping mechanisms. Additionally, the study will assess psychological well-being and weight changes and their consequent influence on obesity-associated comorbid conditions.

Adult patients with coexisting obesity and BED presenting at the Obesity clinic at Haukeland University Hospital, Bergen, Norway, will be included Patients will be divided into two groups: Group-GLP1 (n = 40), who will use GLP-1 analogues, and Group-NoMED (n = 40), who will not use appetite suppressants. Both groups will otherwise follow the routine standardized patient care pathway with follow-up controls every four months and participation in CBT group therapy sessions.

Changes in symptoms of BED, alternative harmful coping strategies and mental health will be recorded at baseline and 12 months using patient-reported questionnaires, as well as anthropometric and biochemical data.

02

Conditions studied

  • Binge Eating Disorder Associated With Obesity
  • Binge Eating Disorder
  • Eating Disorder Binge
  • Eating Disorders
  • GLP-1
  • CBT
  • Obesity &Amp; Overweight
03

In context

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 50 are open to participants now.

This study's planned enrollment of 80 is below the median of 118 across 35 observational studies indexed under Binge-Eating Disorder.

Browse Binge-Eating Disorder studies →

Lead sponsor

Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with obesity and binge eating disorder.

The study will enroll patients with concomitant severe obesity and BED who are referred to the Obesity clinic at Haukeland University Hospital, Norway. All potentially eligible participants will be routinely screened for BED and EDE interview (gold standard) will be used to formally diagnose BED according to the DSM-5.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Severe obesity defined as >40 kg/m2 or 35 kg/m2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, osteoarthritis and polecystic ovary syndrome
  2. Age between 18 to 65 years
  3. Diagnosis of BED according to criteria
  4. Willingness to participate and provide
  5. Able to understand and communicate in Norwegian

Exclusion criteria

Exclusion criteria

  1. Pregnant or lactating women, as well as women planning pregnancy within one year.
  2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic and antipsychotic medication)
  3. Renal failure with estimated less than 30 mL/min/1,73m2
  4. Liver failure with either ASAT and/or ALAT 5 times upper reference limit, or ALP and/or GT more than 3 times upper reference limit, or clinical signs of liver decompensation
  5. Active cancer
  6. Previous medullary thyroid cancer
  7. Previous pancreatitis
  8. Active substance abuse (but previous drug abuse accepted)
  9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.
  10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program
  11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and/or quality of study data.
  12. Previous bariatric surgery
  13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and/or naltrexone/bupropion) within the last 6 months
  14. Participation in another clinical study involving an medicinal product within 1 month prior to study inclusion
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group-GLP1

    Participants receiving standard lifestyle treatment including CBT-E group therapy and individual clinical consultations, in combination with a GLP-1 analogue prescribed by their physician (e.g., liraglutide, semaglutide, or tirzepatide) for weight management. GLP-1 analogue selection, dosage, and duration follow routine clinical practice.

    Drug: GLP-1 · Behavioral: CBTe Group Therapy

  • Group-NoMED

    Participants receiving standard lifestyle treatment including CBT-E group therapy and individual clinical consultations, but without use of GLP-1 analogues or other appetite-suppressing medications.

    Behavioral: CBTe Group Therapy

Interventions

  • DrugGlucagon-Like Peptide 1Studies of Glucagon-Like Peptide 1Glucagon-Like Peptide 1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subcutaneous GLP-1 receptor agonist prescribed for weight management according to routine clinical practice. Acceptable agents include liraglutide (up-titrated to ≤ 3.0 mg daily), semaglutide (≤ 2.4 mg weekly), or tirzepatide (≤ 15 mg weekly). Dose escalation and maintenance follow approved product labels and treating-physician judgment. Planned treatment duration: 12 months or longer.

  • BehavioralCBTe Group Therapy

    Ten weekly 2-hour group sessions based on Cognitive Behavioral Therapy-Enhanced (CBT-E) plus individualized lifestyle consultations every 4 months over a 12-month period. Content targets eating patterns, weight-management behaviors, and emotion-regulation skills. Delivered by trained multidisciplinary staff at the Obesity Centre.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in EDE-Q Global Score From Baseline to 12 Months

    The Eating Disorder Examination Questionnaire (EDE-Q, version 6.0) global score is a validated measure of core eating disorder psychopathology, ranging from 0 to 6, with higher scores indicating greater symptom severity. The EDE-Q comprises 28 items and assesses cognitive and behavioral symptoms over the past 28 days, including four subscales: restraint, eating concern, shape concern, and weight concern. This outcome measures the mean change in global score from baseline to 12-month follow-up, comparing participants receiving GLP-1 analogue treatment (Group-GLP) versus those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Proportion of Participants With Increase in Composite Harmful Coping Endpoint (CHCE) From Baseline to 12 Months

    The Composite Harmful Coping Endpoint (CHCE) captures the emergence of new harmful coping behaviors from baseline to 12-month follow-up. It is defined as a binary outcome, scored as positive if any of the following occur: * Deliberate self-harm (DSHI score \> 0) * Alcohol misuse (AUDIT \>= 8 for men, \>= 6 for women) * Drug misuse (DUDIT \> 6 for men, \> 2 for women) Each of the three components is dichotomized using validated clinical thresholds. Participants with no indication at baseline who cross threshold for any of the three domains at 12 months are considered to have developed a new harmful coping strategy (CHCE = 1). The outcome will compare the proportion of participants with CHCE = 1 between Group-GLP and Group-NoMED. DSHI; Deliberate Self-Harm Inventory (range 0-17, higher is worse), AUDIT; Alcohol Use Disorders Identification Test (range 0-40, higher is worse), DUDIT; Drug Use Disorders Identification Test (range 0-44, higher is worse)

    Time frame: Baseline and 12 months

Other outcomes

  1. Qualitative Evaluation of Patient Experiences With Combined CBT and GLP-1 Treatment

    A subset of study participants (n = 12) receiving GLP-1 analogue treatment will be invited to participate in structured in-depth interviews at 12-month follow-up. Interviews will explore patient experiences related to appetite regulation, eating habits, emotion regulation, and coping strategies during the treatment period. Interviews will be audio-recorded, transcribed, and analyzed using thematic content analysis. This qualitative outcome complements quantitative endpoints by providing insight into subjective treatment experiences.

    Time frame: 12 months

  2. Mean Difference in Change in AUDIT Score Between Groups From Baseline to 12 Months

    The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item screening tool developed by the WHO to assess alcohol consumption, drinking behaviors, and alcohol-related problems. Each item is scored from 0 to 4, yielding a total score range of 0 to 40. Higher scores indicate more severe alcohol-related problems. This outcome assesses the mean difference in AUDIT score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: From baseline to 12 months

  3. Mean Difference in Change in DUDIT Score Between Groups From Baseline to 12 Months

    The Drug Use Disorders Identification Test (DUDIT) is an 11-item screening tool for drug misuse, with total scores ranging from 0 to 44. Higher scores indicate greater severity of drug-related problems. This outcome assesses the mean difference in DUDIT score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  4. Mean Difference in Change in DSHI Score Between Groups From Baseline to 12 Months

    The Deliberate Self-Harm Inventory (DSHI) is a 17-item self-report questionnaire assessing the presence of specific self-injurious behaviors. Each item is scored 0 (absent) or 1 (present), yielding a total score ranging from 0 to 17. Higher scores reflect a greater number of different self-harm methods. This outcome assesses the mean difference in DSHI score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  5. Mean Difference in Change in DERS Score Between Groups From Baseline to 12 Months

    The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report questionnaire that assesses emotional dysregulation across six domains, including nonacceptance of emotional responses, difficulties in goal-directed behavior, impulse control difficulties, lack of emotional awareness, limited access to emotion regulation strategies, and lack of emotional clarity. Total scores range from 36 to 180, with higher scores indicating greater emotion regulation difficulties. This outcome assesses the mean difference in DERS score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  6. Mean Difference in Change in BDI-II Score Between Groups From Baseline to 12 Months

    The Beck Depression Inventory-II (BDI-II) is a 21-item self-report questionnaire used to assess the severity of depressive symptoms over the past two weeks. Each item is scored from 0 to 3, producing a total score range from 0 to 63. Higher scores indicate more severe depressive symptoms. This outcome assesses the mean difference in BDI-II score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  7. Mean Difference in Change in BAI Score Between Groups From Baseline to 12 Months

    The Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire designed to measure the severity of anxiety symptoms over the past week. Each item is scored from 0 to 3, yielding a total score range from 0 to 63. Higher scores indicate more severe anxiety symptoms. This outcome assesses the mean difference in BAI score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  8. Mean Difference in Change in CIA Score Between Groups From Baseline to 12 Months

    The Clinical Impairment Assessment Questionnaire (CIA) is a 16-item self-report measure that assesses psychosocial impairment secondary to eating disorder symptoms over the past 28 days. Total scores range from 0 to 48, with higher scores indicating greater functional impairment. This outcome assesses the mean difference in CIA score change from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  9. Mean Difference in Change in Body Weight and BMI Between Groups From Baseline to 12 Months

    Body weight (in kilograms) and Body Mass Index (BMI, in kg/m²) are measured at baseline and 12-month follow-up. Body weight is measured by InBody 770. This outcome assesses the mean difference in change in body weight and BMI between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  10. Mean Difference in Change in Systolic and Diastolic Blood Pressure Between Groups From Baseline to 12 Months

    Systolic and diastolic blood pressure are measured in mmHg using an automated oscillometric device (Welch Allyn) at baseline and 12-month follow-up. This outcome assesses the mean difference in change in blood pressure between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

  11. Mean Difference in Change in Biochemical Markers of Metabolic Disease Between Groups From Baseline to 12 Months

    Fasting blood samples are analyzed for metabolic markers including high-sensitive C-reactive protein (CRP), hemoglobin A1c (HbA1c), total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides. Values are reported in standard clinical units (e.g., mmol/L or % for HbA1c). This outcome assesses the mean difference in change in these biochemical markers from baseline to 12-month follow-up between participants receiving GLP-1 analogues (Group-GLP) and those not receiving appetite suppressants (Group-NoMED).

    Time frame: Baseline and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Jun 29, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Nov 5, 2027
CompletionEst.
Dec 31, 2028
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07042672
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Jul 1, 2025
Primary completion
Nov 5, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 15, 2025

Study contacts

Malin M Kleppe, PhD candidate
Contact
malin.mandelid.kleppe@helse-bergen.no
+47 99357771

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion